BioPharma Resources

Drug Trial Radar · NCT06667700

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,082 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,082

Planned (sponsor's estimate)

Start

Dec 2, 2024

Primary completion

Jan 26, 2031

Study completion Jan 26, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other medicines that may react with a treatment and cause an unwanted effect. Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19 virus from copying itself in the body (multiplying). The goal of this study is to learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk.

Conditions

  • Coronavirus Disease (COVID-19)

Interventions

  • MolnupiravirDrug

    Molnupiravir administered orally as two 400 mg film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)

  • PlaceboDrug

    Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced One or More of Following Through Day 29: All-cause Hospitalization, All-cause Mortality, or Covid-19-related Medically-attended Visit (MAV)Time frame: Up to 29 days
  2. Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 5 months
  3. Percentage of Participants Who Discontinued Study Intervention Due to AETime frame: Up to approximately 5 days

Locations

230 sites in 24 countries. Site status is shown where the registry gives one.

  • Cullman Clinical Trials ( Site 3813)

    Cullman, Alabama · Completed

  • Helios Clinical Research ( Site 3826)

    Paradise Valley, Arizona · Recruiting

  • Absolute Clinical Research ( Site 3709)

    Phoenix, Arizona · Completed

  • Clinica de Salud del Valle de Salinas ( Site 3825)

    Castroville, California · Recruiting

  • Ascada Health PC dba Ascada Research ( Site 3750)

    Fullerton, California · Completed

  • Pacific Clinical Studies ( Site 3827)

    Los Alamitos, California · Recruiting

  • Valley Clinical Trials, Inc. ( Site 3707)

    Northridge, California · Recruiting

  • FOMAT Medical Research ( Site 3720)

    Oxnard, California · Recruiting

  • Paradigm Clinical Research, LLC ( Site 3785)

    San Diego, California · Recruiting

  • Optimus Medical ( Site 3817)

    San Francisco, California · Recruiting

  • Millennium Clinical Trials ( Site 3758)

    Westlake Village, California · Recruiting

  • Paradigm Clinical Research Centers, Inc ( Site 3718)

    Wheat Ridge, Colorado · Recruiting

  • Encore Medical Research of Boynton Beach ( Site 3701)

    Boynton Beach, Florida · Recruiting

  • Prestige Clinical Research Center ( Site 3722)

    Coral Gables, Florida · Recruiting

  • Prestige Clinical Research ( Site 3830)

    Homestead, Florida · Recruiting

  • Accel Research Sites Network - St. Pete-Largo Clinical Research Unit ( Site 3779)

    Largo, Florida · Recruiting

  • Clinical Site Partners, LLC dba Flourish Research ( Site 3717)

    Leesburg, Florida · Recruiting

  • Advanced Pulmonary Research Institute ( Site 3781)

    Loxahatchee Groves, Florida · Active not recruiting

  • Southern Clinical Research ( Site 3773)

    Miami, Florida · Recruiting

  • Florida Pharmaceutical Research and Associates ( Site 3763)

    Miami, Florida · Recruiting

  • Bio-Medical Research LLC ( Site 3804)

    Miami, Florida · Recruiting

  • Bright Research Center ( Site 3746)

    Miami, Florida · Completed

  • Miami Clinical Research ( Site 3729)

    Miami, Florida · Recruiting

  • Reed Medical Research ( Site 3761)

    Miami, Florida · Recruiting

  • Palm Springs Community Health Center ( Site 3757)

    Miami Lakes, Florida · Recruiting

  • Panax Clinical Research ( Site 3803)

    Miami Lakes, Florida · Recruiting

  • Indago Research and Health Center Inc ( Site 3714)

    Miami Lakes, Florida · Recruiting

  • Combined Research Orlando Phase I-IV ( Site 3797)

    Orlando, Florida · Recruiting

  • CDC Research Institute ( Site 3716)

    Port Saint Lucie, Florida · Recruiting

  • New Tampa Health ( Site 3764)

    Tampa, Florida · Recruiting

  • Clinical Research Trials of Florida ( Site 3703)

    Tampa, Florida · Recruiting

  • Precision Research Center ( Site 3704)

    Tampa, Florida · Recruiting

  • Encore Medical Research - Weston ( Site 3708)

    Weston, Florida · Completed

  • Balanced Life Health Care Solutions/SKYCRNG ( Site 3713)

    Lawrenceville, Georgia · Completed

  • Renew Health Clinical Research ( Site 3760)

    Snellville, Georgia · Recruiting

  • Rophe Adult and Pediatric Medicine/SKYCRNG ( Site 3816)

    Union City, Georgia · Completed

  • Paradigm Clinical Research - Boise ( Site 3841)

    Boise, Idaho · Completed

  • Rush University Medical Center ( Site 3748)

    Chicago, Illinois · Recruiting

  • Duly Health and Care ( Site 3799)

    Lombard, Illinois · Recruiting

  • University of Louisville School of Medicine ( Site 3706)

    Louisville, Kentucky · Recruiting

Showing 40 of 230 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.